Tyra Biosciences, INC Form 4 insider transactions

RA Capital Management reports a stock option grant for director Dr. Jake Simson under the Tyra Biosciences non-employee director compensation program.

Tyra Biosciences Director Rehan Verjee was granted stock options for 13,160 shares of common stock under the company's Non-Employee Director Compensation Program.

Tyra Biosciences Director Susan Moran acquired stock options under the company's Non-Employee Director Compensation Program.

Tyra Biosciences Director Jake Simson acquired stock options under the company's Non-Employee Director Compensation Program.

Tyra Biosciences Director Adele M. Gulfo acquired stock options under the company's Non-Employee Director Compensation Program.

Tyra Biosciences Director Robert J. More acquired stock options for 13,160 shares of common stock under the company's Non-Employee Director Compensation Program.

Tyra Biosciences Director Stephen Rothenberg acquired stock options for 13,160 shares of common stock.

Bhavesh Ashar, Chief Operating Officer of Tyra Biosciences, Inc., reported a transaction involving the acquisition of restricted stock units and stock options.

Yuliya Rueb, Vice President of Finance at Tyra Biosciences, acquired stock options and restricted stock units.

Director Habib J. Dable was granted 44,400 stock options in Tyra Biosciences, Inc. as part of a standard equity incentive.

Tyra Biosciences Director Gilla Kaplan exercised stock options and subsequently sold over 67,000 shares of common stock for approximately $2.5 million.

Tyra Biosciences Chief Financial Officer Alan Fuhrman acquired 1,376 shares of common stock through an employee stock purchase plan.

Tyra Biosciences President and CEO, Todd Harris, acquired 1,463 shares of common stock through the company's Employee Stock Purchase Plan.

Tyra Biosciences' Chief Discovery Officer, Daniel Bensen, sold 8,000 shares of common stock on February 12, 2026, under a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Discovery Officer, Daniel Bensen, sold 8,000 shares of common stock on January 12, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Tyra Biosciences Director Robert J. More sold 10,000 shares of common stock at $25 per share on December 19, 2025, under a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Discovery Officer, Daniel Bensen, reported the sale of 8,000 common shares on December 12, 2025, executed under a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Operating Officer, Bhavesh Ashar, was granted 300,000 stock options with an exercise price of $20.81, vesting over four years.

Tyra Biosciences Director Robert J. More sold 246,871 shares of common stock for approximately $20.25 per share through a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Operating Officer, Daniel Bensen, sold a total of 125,589 shares of common stock in two transactions in November 2025 under a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Operating Officer, Daniel Bensen, sold 131,411 shares of common stock in November 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Tyra Biosciences' Chief Financial Officer, Alan Fuhrman, acquired 701 shares of common stock at $9.129 per share through the company's Employee Stock Purchase Plan.

Tyra Biosciences' Chief Financial Officer, Alan Fuhrman, was granted 170,000 stock options with a $10.75 exercise price, vesting monthly over four years.

Tyra Biosciences' Chief Operating Officer, Daniel Bensen, was granted 170,000 stock options with a $10.75 exercise price, vesting over four years.

Tyra Biosciences' Chief Medical Officer, Douglas J. Warner, was granted 200,000 stock options with a $10.75 exercise price and a 10-year expiration.

Tyra Biosciences' President and CEO, Todd Harris, acquired 570,000 stock options with an exercise price of $10.75, vesting monthly over four years.

Tyra Biosciences, Inc. Director Gilla Kaplan sold a total of 9,578 shares of common stock in mid-June 2025, as disclosed in a recent SEC Form 4 filing, with transactions executed under a Rule 10b5-1 trading plan.

RA Capital Management, a significant institutional investor and director group, has increased its beneficial ownership in Tyra Biosciences, Inc. through recent open market purchases of common stock.

Gilla Kaplan, a Director at Tyra Biosciences, Inc. (TYRA), has reported the sale of 51,814 shares of common stock over three separate transactions in mid-June 2025.

RA Capital Management, a prominent institutional investor and 10% owner of Tyra Biosciences, Inc., has increased its beneficial ownership by acquiring an additional 186,850 shares of common stock.